Miles Jennings’ practice includes representing public and private technology, life science, cryptocurrency, and other emerging companies, as well as the entities that finance them. He advises emerging companies through their entire lifecycle, from formation through growth stages and exits. In particular, his practice focuses on venture capital financings, cryptocurrencies, initial coin offerings and prefunctional token sale financing structures, public securities offerings, mergers and acquisitions, and general company representation.
Mr. Jennings received his JD, magna cum laude, from the Pepperdine University School of Law in 2009, where he was a fellow in the Palmer Center for Entrepreneurship & the Law and lead articles editor of the Pepperdine Law Review. He received his BS in Mechanical Engineering from the University of California, Los Angeles, in 2006.
Mr. Jennings’ technology and cryptocurrency representative work includes:
- ConsenSys, ConsenSys Ventures, Tachyon Accelerator
- Token Foundry
- Meritech Capital
- Formation 8 and 8VC
- Bill and Melinda Gates Foundation
- Andreessen Horowitz
- Bitwise
- Halo Neuro
- Clarify Health Solutions
- Zeus Living
- Nanosys
- OpenGov
- PresenceLearning
- Pipedrive
- Proterra
- Kymeta
- Steel House
Mr. Jennings’ life sciences representative work includes:
- CytomX Therapeutics (public)
- Unity Biotechnology (public)
- Aimmune Therapeutics (public)
- Corvus Pharmaceuticals (public)
- Menlo Therapeutics (public)
- Myokardia (public)
- Hexagon Bio
- Omniome
- Mercator Medsystems
- Indalo Therapeutics
- Abingworth